WO2004065569A3 - Multi-functional antibodies - Google Patents
Multi-functional antibodies Download PDFInfo
- Publication number
- WO2004065569A3 WO2004065569A3 PCT/US2004/001808 US2004001808W WO2004065569A3 WO 2004065569 A3 WO2004065569 A3 WO 2004065569A3 US 2004001808 W US2004001808 W US 2004001808W WO 2004065569 A3 WO2004065569 A3 WO 2004065569A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibodies
- functional antibodies
- present
- antigen recognition
- reactive site
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Abstract
The present invention provides antibodies comprising an antigen recognition domain that specifically binds to a metal chelate: mutant antibodies comprising a reactive site not present in the wild-type of the antibody, wherein the reactive site is in a position proximate to or within the antigen recognition domain; and methods of using such antibodies to diagnose and treat disease.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/350,555 US7528235B2 (en) | 2003-01-23 | 2003-01-23 | Multi-functional antibodies |
US10/350,555 | 2003-01-23 | ||
US10/625,047 US7820787B2 (en) | 2003-01-23 | 2003-07-22 | Multi-functional antibodies |
US10/625,047 | 2003-07-22 | ||
US10/631,258 | 2003-07-31 | ||
US10/631,258 US20050026263A1 (en) | 2003-07-31 | 2003-07-31 | Multi-functional antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004065569A2 WO2004065569A2 (en) | 2004-08-05 |
WO2004065569A3 true WO2004065569A3 (en) | 2005-03-24 |
Family
ID=32776952
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/001808 WO2004065569A2 (en) | 2003-01-23 | 2004-01-23 | Multi-functional antibodies |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2004065569A2 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8877190B2 (en) | 2006-11-30 | 2014-11-04 | Abbvie Inc. | Aβ conformer selective anti-Aβ globulomer monoclonal antibodies |
US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
US9146244B2 (en) | 2007-06-12 | 2015-09-29 | Ac Immune S.A. | Polynucleotides encoding an anti-beta-amyloid monoclonal antibody |
US9176150B2 (en) | 2003-01-31 | 2015-11-03 | AbbVie Deutschland GmbH & Co. KG | Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof |
US9221900B2 (en) | 2010-07-30 | 2015-12-29 | Ac Immune S.A. | Methods for identifying safe and functional humanized antibodies |
US9403902B2 (en) | 2007-10-05 | 2016-08-02 | Ac Immune S.A. | Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody |
US9540432B2 (en) | 2005-11-30 | 2017-01-10 | AbbVie Deutschland GmbH & Co. KG | Anti-Aβ globulomer 7C6 antibodies |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060063209A1 (en) * | 2004-08-20 | 2006-03-23 | The Regents Of The University Of California | Engineered antibody fragment that irreversibly binds an antigen |
KR101439828B1 (en) | 2005-11-30 | 2014-09-17 | 애브비 인코포레이티드 | Monoclonal antibodies against amyloid beta protein and uses thereof |
WO2007131242A2 (en) * | 2006-05-05 | 2007-11-15 | The Regents Of The University Of California | Streptavidin-biotin-link antibody-hapten system |
KR101605207B1 (en) | 2006-07-14 | 2016-03-22 | 에이씨 이뮨 에스.에이. | Humanized antibody against amyloid beta |
BRPI0812484A2 (en) * | 2007-06-12 | 2018-06-05 | Ac Immune Sa | monoclonal antibody, light chain and heavy chain variable regions, isolated cdr, polynucleotide, therapeutic composition, methods for treating disease and disorder, for producing an antibody, for treating or alleviating the effects of disease and disorder, for reducing plaque burden in an individual's brain, to reduce the amount of plaque in an individual's brain, to decrease the total amount of soluble spruce in an individual's brain, to retain or increase an individual's cognitive memory capacity, to diagnose from or to diagnose a predisposition to an amyloid-associated disease or condition in a patient, to determine the extent of amyloidogenic plaque burden in an individual's tissue, to monitor minimal residual disease in an individual, and to predict an individual's responsiveness, cell line , test kit, epitope fir |
US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
EP3533803B1 (en) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antibodies |
ES2604012T3 (en) * | 2012-07-04 | 2017-03-02 | F. Hoffmann-La Roche Ag | Covalently bound antigen-antibody conjugates |
MX353951B (en) | 2012-07-04 | 2018-02-07 | Hoffmann La Roche | Anti-theophylline antibodies and methods of use. |
CA2872192A1 (en) | 2012-07-04 | 2014-01-09 | F. Hoffmann-La Roche Ag | Anti-biotin antibodies and methods of use |
BR112016012666A2 (en) | 2014-01-03 | 2017-09-26 | Hoffmann La Roche | conjugate, antibodies, pharmaceutical formulation and uses of conjugate |
JP6521464B2 (en) * | 2014-01-03 | 2019-05-29 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Covalently linked polypeptide toxin-antibody conjugates |
EP3089996B1 (en) | 2014-01-03 | 2021-07-28 | F. Hoffmann-La Roche AG | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles |
KR20170026362A (en) | 2014-06-26 | 2017-03-08 | 에프. 호프만-라 로슈 아게 | Anti-brdu antibodies and methods of use |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5958374A (en) * | 1994-03-28 | 1999-09-28 | The Regents Of The University Of California | Method for preparing radionuclide-labeled chelating agent-ligand complexes |
WO2001022922A2 (en) * | 1999-09-27 | 2001-04-05 | The Regents Of The University Of California | Engineering antibodies that bind irreversibly |
US20030124057A1 (en) * | 2001-11-28 | 2003-07-03 | Immunomedics, Inc. | Anti-DOTA antibody |
-
2004
- 2004-01-23 WO PCT/US2004/001808 patent/WO2004065569A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5958374A (en) * | 1994-03-28 | 1999-09-28 | The Regents Of The University Of California | Method for preparing radionuclide-labeled chelating agent-ligand complexes |
WO2001022922A2 (en) * | 1999-09-27 | 2001-04-05 | The Regents Of The University Of California | Engineering antibodies that bind irreversibly |
US20030124057A1 (en) * | 2001-11-28 | 2003-07-03 | Immunomedics, Inc. | Anti-DOTA antibody |
Non-Patent Citations (6)
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9176150B2 (en) | 2003-01-31 | 2015-11-03 | AbbVie Deutschland GmbH & Co. KG | Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof |
US9540432B2 (en) | 2005-11-30 | 2017-01-10 | AbbVie Deutschland GmbH & Co. KG | Anti-Aβ globulomer 7C6 antibodies |
US8877190B2 (en) | 2006-11-30 | 2014-11-04 | Abbvie Inc. | Aβ conformer selective anti-Aβ globulomer monoclonal antibodies |
US9359430B2 (en) | 2006-11-30 | 2016-06-07 | Abbvie Inc. | Abeta conformer selective anti-Abeta globulomer monoclonal antibodies |
US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
US9146244B2 (en) | 2007-06-12 | 2015-09-29 | Ac Immune S.A. | Polynucleotides encoding an anti-beta-amyloid monoclonal antibody |
US9403902B2 (en) | 2007-10-05 | 2016-08-02 | Ac Immune S.A. | Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody |
US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
US9221900B2 (en) | 2010-07-30 | 2015-12-29 | Ac Immune S.A. | Methods for identifying safe and functional humanized antibodies |
Also Published As
Publication number | Publication date |
---|---|
WO2004065569A2 (en) | 2004-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004065569A3 (en) | Multi-functional antibodies | |
WO2003074679A3 (en) | Antibody optimization | |
ZA200702879B (en) | Single domain antibodies against TNFR1 and methods of use therefor | |
NZ599683A (en) | Anti-ilt7 antibody | |
WO2007022520A3 (en) | Antibody-mediated enhancement of immune response | |
WO2007131242A3 (en) | Streptavidin-biotin-link antibody-hapten system | |
WO2002016401A3 (en) | Monoclonal antibody ds6, tumor-associated antigen ca6, and methods of use thereof | |
WO2002075274A3 (en) | Method and kit for following neurodegenerative diseases | |
EP1139101A3 (en) | Immunoassay for c-reactive protein | |
WO2003060080A3 (en) | Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them | |
NZ607711A (en) | Antibodies directed to her-3 and uses thereof | |
WO2004001381A8 (en) | Novel raag10 cell surface target and a family of antibodies recognizing that target | |
WO2006102200A3 (en) | Docetaxel immunoassay | |
NZ595450A (en) | Antibodies to M-CSF | |
WO2004022717A3 (en) | Minimally immunogenic variants of humanized col-1 antibody against carcinoembryonic antigen | |
WO2006086208A3 (en) | 5-fluoro-uracil immunoassay | |
EP3300739A3 (en) | Antibodies and related molecules that bind to 161p2f10b proteins | |
WO2006015098A3 (en) | Taxol immunoassay | |
WO2005026209A3 (en) | Monoclonal antibodies against hmgb1 | |
TR200202799T3 (en) | Humanized antibodies that sequence the AB peptide | |
AU2001268855A1 (en) | Single-domain antigen-binding antibody fragments derived from llama antibodies | |
NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
WO2005010048A3 (en) | Rg1 antibodies and uses thereof | |
WO2003032814A3 (en) | Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof | |
WO2003048302A3 (en) | Identifying anti-tumor targets or agents by lipid raft immunization and proteomics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |